Atox Bio

Atox Bio’s initial focus is on patients with Necrotizing Soft Tissue Infections (NSTI, “flesh eating bacteria”), a rare, life threatening, infection for which no current therapy exists. Reltecimod (AB103), their lead asset, is an immunomodulator that modulates the host response to infections by various pathogens via a novel target, the dimer interface of the CD28 T-cell receptor. It is designed to enhance resolution of organ failure in conditions associated with severe, acute inflammation, such as NSTI and sepsis.